| 000 | 01298 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250518080841.0 | ||
| 264 | 0 | _c20201105 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1879-0712 | ||
| 024 | 7 |
_a10.1016/j.ejphar.2020.172913 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOcker, Matthias | |
| 245 | 0 | 0 |
_aChallenges and opportunities in drug development for nonalcoholic steatohepatitis. _h[electronic resource] |
| 260 |
_bEuropean journal of pharmacology _cMar 2020 |
||
| 300 |
_a172913 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDrug Development |
| 650 | 0 | 4 |
_aFibrosis _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aInflammation _xcomplications |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 |
_aLiver Neoplasms _xcomplications |
| 650 | 0 | 4 |
_aMetabolic Diseases _xcomplications |
| 650 | 0 | 4 |
_aNon-alcoholic Fatty Liver Disease _xdrug therapy |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tEuropean journal of pharmacology _gvol. 870 _gp. 172913 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejphar.2020.172913 _zAvailable from publisher's website |
| 999 |
_c30508055 _d30508055 |
||